ModifiedUnitedHealthcarePolicy 2026T0493II

Neurophysiologic Testing and Monitoring

Defines UnitedHealthcare coverage stance for neurophysiologic and electrodiagnostic tests (e.g., nerve conduction studies, EMG, QST, VEPs, wearable physiologic monitors) for Commercial and Individual Exchange plans.

Policy Summary

PayerUnitedHealthcare

PolicyNeurophysiologic Testing and Monitoring

Policy CodePolicy 2026T0493II

Change TypeCode removals and content updates

Effective DateJan 1, 2026

Next Review Date

Key ActionVerify member benefits and use the updated applicable code list (codes 95999 and A9279 removed) when submitting prior authorization and claims.

SourceLink

POLICY UPDATE CHANGES

Removed CPT/HCPCs codes 95999 and A9279 from the applicable codes list.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect most current information.

Created shared policy version to support application to Oxford plan membership.

Removed CPT/HCPCs codes 95999 and A9279.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

Created shared policy version to support application to Oxford plan membership.

2CPT/HCPCS codes removed from policy

Commercial & ExchangeApplies to plan types

0.91

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Mean sensitivity for GTCS detection (wearables)

2.1/24hFalse alarm rate (wearables)

multipleUnproven / not medically necessary services

Coverage Criteria and Clinical Stance

Medically Necessary Indications

Covered when ALL of the following are met:

Indications for NCS with or without needle EMG: Nerve conduction studies with or without standard late responses (e.g., F-wave and H-reflex) and neuromuscular junction testing when performed in conjunction with needle electromyography are proven and medically necessary for known or suspected peripheral neuropathy/polyneuropathy; plexopathy; neuromuscular junction disorders; myopathy; motor neuron disease; radiculopathy (cervical, thoracic, or lumbosacral); or for treatment guidance such as muscle localization for botulinum toxin injections.

NCS without needle EMG allowable exceptions: Nerve conduction studies with or without standard late responses when performed without needle electromyography are medically necessary for individuals with the above disorders when any of the following apply: individuals treated with anticoagulants; individuals with lymphedema; or individuals being evaluated for carpal tunnel syndrome.

Unproven / Not Medically Necessary

Not medically necessary / Unproven services:

Unproven NCS uses: Nerve conduction studies for all other conditions are unproven and not medically necessary due to insufficient evidence of efficacy.

Automated/portable NCS devices: Non-invasive automatic, portable, or automated point-of-care nerve conduction monitoring systems that test only distal motor latencies and conduction velocities for electrodiagnostic purposes are unproven and not medically necessary.

Other unproven neurophysiologic tests: Macro-EMG, physiologic monitoring of seizure or movement disorders using wearable accelerometer/EDA/gyroscope devices (e.g., wrist-devices, smartwatches), SEMG-based seizure monitoring systems, surface electromyography (sEMG), surface mechanomyography (sMMG), quantitative sensory testing (including monofilament, pressure-specified sensory testing, computer-assisted sensory exams, and current perception threshold/CPT testing), and visual evoked potential testing for diagnosing and evaluating glaucoma are unproven and not medically necessary due to insufficient evidence of efficacy.

Clinical indications and performance standards for electrodiagnostic testing

Covered when supported by clinical indication and performed per professional standards

Standard NCS/EMG indications: Electrodiagnostic testing (NCS and needle EMG) is indicated for focal entrapment neuropathies, traumatic nerve lesions, generalized neuropathies, neuromuscular junction disorders, symptom-based presentations (pain, weakness, paresthesia) when pre-test evaluations are inconclusive, radiculopathy, plexopathy, myopathy, and for localization when guiding injections.

Based on AANEM model policy and indications.

When EDX testing is particularly recommended for neuropathy: Consider electrodiagnostic testing when history/physical and standard neuropathy labs do not indicate etiology; symptoms are moderate to severe; presentation is atypical (predominant motor, proximal deficits, or asymmetry); there is rapid progression; signs suggest another disorder; duration or severity are unknown; family history suggests hereditary neuropathy; or there is exposure to neurotoxic agents.

From AANEM distal symmetric polyneuropathy guidance.

Performance and supervision requirements: Testing must be performed using equipment that assesses all signal parameters (screening-only devices are not acceptable); testing should be performed by or under direct supervision of a physician trained in electrodiagnostic medicine; the EMG component must be performed by a trained physician; and one attending physician should supervise and perform all components with real-time interpretation preferred.

Evidence-based coverage stance for specialized tests and wearables

Coverage stance based on current evidence

Macro-EMG and point-of-care NCS: Current peer-reviewed evidence is weak for Macro-EMG and for point-of-care/portable nerve conduction devices; additional robust studies demonstrating consistent, patient-relevant outcomes are needed before routine coverage is supported.

Macro-EMG and point-of-care NCS evidence considered weak.

Wearable devices for seizure detection: Wearable accelerometer- and surface EMG–based devices show high sensitivity for detecting tonic‑clonic seizures in monitored studies (mean sensitivity ~0.91) but have variable and sometimes substantial false alarm rates (mean ~2.1 per 24 hours); the evidence is heterogeneous and mostly from controlled or short-term settings, requiring further validation in ambulatory, diverse populations.mean sensitivity ~0.91; FAR ~2.1/24h

Systematic reviews/meta-analyses report high sensitivity but heterogeneous FAR and study settings.

VEPs for glaucoma: Visual evoked potentials, including isolated‑check VEP (icVEP) and multifocal VEP, have been investigated for glaucoma detection and show promising diagnostic performance in small studies, but heterogeneity, small samples, and protocol variability limit generalizability and further study is required before replacing standard tests.

Wearable seizure detection - medically necessary conditions

Covered when ALL of the following are met

Wearable device for seizure detection (GTCS/FBTCS): The device is a clinically validated wearable specifically for detecting generalized tonic‑clonic seizures (GTCS) or focal‑to‑bilateral tonic‑clonic seizures (FBTCS); the individual has significant safety concerns (for example, unsupervised sleeping, lives alone, or otherwise at risk of delayed intervention); and device performance data (including sensitivity and false alarm rate) are provided showing acceptable detection in settings comparable to intended use.sensitivity ~0.9 reported; FAR variable (~2.1/24h)

ILAE‑IFCN gives a conditional recommendation for use in safety scenarios; documentation should address FAR and intended response time (e.g., alarm leading to intervention within ~5 minutes).

Wearable movement monitoring in Parkinson disease - coverage conditions

Covered when ALL of the following are met

Objective movement monitoring for Parkinson disease (informing management): The device provides objective multi‑day ambulatory monitoring (for example, Personal KinetiGraph worn ≥6 days) with clinician review and documentation that device-derived data added novel, actionable information that changed or could change management (such as medication adjustment or referral for device-assisted therapy).PKG: ≥6 days wear; classifier examples: sensitivity 89% and specificity 86.6% reported

Evidence shows PKG influenced management in a subset of cases; classifiers and algorithms require independent validation.

Quantitative Sensory Testing - evidence limitations

Not covered / Insufficient evidence when ANY of the following apply

QST for predicting individual treatment outcomes: Use of quantitative sensory testing (QST) as a standalone test to predict individual patient outcomes (for example, surgical or conservative treatment response) is not supported by consistent high‑quality evidence and therefore is not covered/insufficient evidence.evidence described as very low to inconsistent

Systematic reviews conclude more high‑quality studies are needed before routine prognostic use is supported.

QST — evidence limitations and recommended constraints

Summary of professional society conclusions and implications for coverage

QST validity and use: Professional society reviews (AAN, AANEM) conclude QST exhibits wide variability in sensitivity, specificity, and reproducibility across instruments and protocols; results depend on instrument, protocol, calibration, and subject cooperation, and use should be limited to instruments and methodologies demonstrated to be reproducible.

Reproducibility ranges from poor to excellent; strict calibration and protocols required.

sEMG and sEMG-based monitoring — limited/variable evidence

Summary of evidence for sEMG and sEMG-based devices

sEMG clinical utility: Current evidence for surface EMG (sEMG) across indications (seizure detection, respiratory monitoring during mechanical ventilation, ALS monitoring, trunk muscle activity in spinal cord injury, temporomandibular disorder diagnosis) is weak or variable; studies show methodological heterogeneity, small sample sizes, and inconsistent diagnostic accuracy; feasibility has been demonstrated for some devices but false alarm rates and limited generalizability are concerns.

Systematic reviews and prospective trials report feasibility but call for larger well‑designed studies.

sMMG — insufficient evidence

Surface mechanomyography (sMMG)

sMMG evidence: Few published studies address surface mechanomyography with concurrent inertial measurement unit sensors for multi‑joint or musculoskeletal assessment; evidence is insufficient to conclude a beneficial effect on health outcomes.

Coverage implication: Until robust evidence demonstrates outcome benefit, sMMG systems should be considered investigational or not medically necessary.

icVEP — promising but insufficient for broad replacement of standard tests

Isolated‑check visual evoked potentials (icVEP) for glaucoma

icVEP diagnostic performance: Small cross‑sectional studies and systematic reviews report icVEP sensitivity roughly 62–95% and specificity roughly 51–93% with reported signal‑to‑noise (SNR) cutoffs (examples: 0.85, 0.93, 1.0); heterogeneity, small samples, and protocol variability limit generalizability and preclude replacing standard diagnostic tests.SNR cutoffs reported (0.85, 0.93, 1.0)

Promising but insufficient evidence for broad clinical replacement of standard automated perimetry or OCT.

This policy does not address intraoperative neurophysiologic testing. Refer to institution-specific intraoperative monitoring protocols and applicable specialty guidance for operative monitoring requirements.

Certain devices and techniques are identified in the evidence review as having weak or limited supporting evidence and are considered investigational or not medically necessary until more robust outcome data are available. Examples include Macro‑EMG and point‑of‑care/portable nerve conduction systems, for which current peer‑reviewed studies are small and do not demonstrate consistent patient‑relevant benefit.

Wearable seizure detection devices are conditionally addressed only for seizure types with clinical validation. Devices that have not been clinically validated for seizure types other than generalized tonic‑clonic seizures (GTCS) or focal‑to‑bilateral tonic‑clonic seizures (FBTCS) (for example many focal seizures or psychogenic nonepileptic seizures) are excluded from clinical recommendation until appropriate validation data are available.

Modalities and specific tests identified as investigational by specialty society model policies are excluded from coverage pending further evidence. Examples called out by professional groups include the current perception threshold / sensory nerve conduction threshold (sNCT) and surface mechanomyography (sMMG) systems, for which there are limited reproducibility data and insufficient evidence of impact on clinical outcomes.

Administrative code updates were made in this policy version. Specifically, CPT/HCPCS codes 95999 and A9279 have been removed from the policy's applicable codes list and should not be used for coverage under this policy version.

Coverage decisions must be made in the context of the member’s specific benefit plan and any applicable federal or state mandates. When applying this policy, always verify the member‑specific benefit plan document, since plan terms or mandates may differ and govern in case of conflict.

The policy explicitly lists technologies and tests considered unproven or not medically necessary based on current evidence. These include, among others, macro‑EMG, automated/portable point‑of‑care NCS devices, surface EMG (sEMG) and sEMG‑based seizure monitors, surface mechanomyography (sMMG), quantitative sensory testing (QST) variants (e.g., monofilament, pressure‑specified, CPT), and visual evoked potential testing for glaucoma.

Routine use of Macro‑EMG, automated/portable point‑of‑care NCS, and many consumer or clinical wearable physiologic recording technologies for seizure or movement detection is not supported by current high‑certainty evidence. Available studies are heterogeneous, often small, and typically conducted in controlled settings, limiting generalizability to routine ambulatory clinical use.

The routine use of Quantitative Sensory Testing (QST) to predict individual patient outcomes (for example, surgical or conservative treatment response) is not supported. Systematic reviews report weak, inconsistent, or very low‑certainty associations; QST does not reliably predict individual outcomes and therefore is considered not medically necessary for that purpose at this time.

Use of surface EMG (sEMG) and surface mechanomyography (sMMG) is limited by weak or inconsistent evidence across indications. When study results are variable and the device output does not demonstrably change clinical management, such uses may be considered not medically necessary until higher‑quality evidence demonstrates clinical utility and reproducibility.

The policy’s list of not medically necessary / unproven services is illustrative, not exhaustive. Specific determinations about whether a test or technology is medically necessary should reference the full policy content, current evidence, and the member’s benefit plan; consult the complete policy text for comprehensive exclusion and NMN listings.

Applicable Codes and Coding Notes

Applicable CPT CodesCPT

0106T	Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation.
0107T	Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation.
0108T	Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia.
0109T	Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia.
0110T	Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation.
0464T	Visual evoked potential, testing for glaucoma, with interpretation and report.
0778T	Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function.
95860	Needle electromyography; 1 extremity with or without related paraspinal areas.
95861	Needle electromyography; 2 extremities with or without related paraspinal areas.
95863	Needle electromyography; 3 extremities with or without related paraspinal areas.

1–10 of 34

1/4

Applicable HCPCS/CPT MiscHCPCS | CPT

A9280	Alert or alarm device, not otherwise classified.
G0255	Current perception threshold/sensory nerve conduction test, (SNCT) per limb, any nerve.
S3900	Surface electromyography (EMG).

Removed CodesCPT | HCPCSNot Covered

95999	Previously listed CPT/HCPCS code removed from policy
A9279	Previously listed CPT/HCPCS code removed from policy

Removed CodesmixedNot Covered

95999	Previously listed CPT/HCPCS code (removed)
A9279	Previously listed CPT/HCPCS code (removed)

Minimum electrodiagnostic components for neuromuscular junction testing — required study components

Minimum NCS componentsAt least one motor and one sensory nerve conduction study should be performed in a clinically involved limb (preferably in the distribution of a nerve studied with repetitive stimulation or SFEMG).

Needle EMG requirementAt least one distal and one proximal muscle should be studied by needle EMG to exclude neuropathy or myopathy associated with abnormal repetitive stimulation or SFEMG.

Association with neuromuscular junction testingNeuromuscular junction testing (repetitive stimulation/SFEMG) may be performed in association with NCS of the same nerves.

icVEP SNR diagnostic cutoffs reported in studies

Reported icVEP SNR cutoffs

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Medical indication for NCS/EMG

Medical indication for NCS and needle EMG: Perform nerve conduction studies (NCS) and needle electromyography (EMG) only when medically indicated by the clinical history and physical examination to answer a specific differential diagnosis (for example: peripheral neuropathy/polyneuropathy, plexopathy, neuromuscular junction disorders, myopathy, motor neuron disease, radiculopathy, focal entrapment neuropathies, traumatic nerve lesions, or to localize muscles for targeted treatment). NCS without needle EMG may be appropriate in select situations (e.g., individuals on anticoagulants, those with lymphedema, or screening for carpal tunnel syndrome), but the testing must be targeted and clinically justified. A complete EDX evaluation typically integrates history, exam, and both NCS and needle EMG when indicated; separate reporting of NCS and EMG results or performing components on different days is generally not consistent with recommended practice.

Indications: peripheral neuropathy, plexopathy, neuromuscular junction disorders, myopathy, motor neuron disease, radiculopathy, focal neuropathies, traumatic lesions, treatment guidance (e.g., muscle localization for botulinum toxin).
NCS alone acceptable only for specific clinical scenarios (e.g., anticoagulation, lymphedema, carpal tunnel screening).

Prior Authorization

Wearable seizure device validation and safety justification

Background and Clinical Context

Neurophysiologic testing, including nerve conduction studies (NCS) and electromyography (EMG), evaluates peripheral nerve conduction and muscle responses and complements history and physical examination when motor or sensory deficits require further evaluation. NCS and needle EMG are frequently performed together; late responses (for example, F‑wave and H‑reflex) provide additional complementary information. Wearable and point‑of‑care automated devices exist but currently lack equivalence to a full electrodiagnostic study performed per professional standards.

Definitions and Terminology

EMG (electromyography) — definition and distinctions (needle EMG, sEMG)

EMG definitionEMG measures muscle response to electrical or nerve stimulation to evaluate nerve and muscle function; it includes needle EMG (NEMG) and surface EMG (sEMG).

Needle EMGRequires insertion of needles through the skin; used to determine whether weakness is due to nerve, neuromuscular junction, or muscle disorder.

Surface EMG (sEMG)Noninvasive recordings from skin electrodes measuring underlying muscle electrical activity; used in contexts from seizure monitoring to trunk muscle assessment.

NCS (nerve conduction studies) — definition and role

NCS definitionNerve conduction studies assess peripheral nerve integrity by measuring conduction velocity, latency, amplitude, and response shape.

Late responses

Policy Summary

PayerUnitedHealthcare

PolicyNeurophysiologic Testing and Monitoring

Policy CodePolicy 2026T0493II

Change TypeCode removals and content updates

Effective DateJan 1, 2026

Next Review Date

Key ActionVerify member benefits and use the updated applicable code list (codes 95999 and A9279 removed) when submitting prior authorization and claims.

SourceLink

On This Page

Based on AANEM recommended practice statements.

Use of NCS without EMG: Nerve conduction studies may be performed without needle EMG only in limited circumstances (e.g., individuals on anticoagulants, with lymphedema, or undergoing carpal tunnel evaluation) and such exceptions should be justified.

AANEM exceptions.

icVEP evidence promising but limited by small studies and variability.

SNR cutoffs reported in studies include 0.85, 0.93, and 1.0.

SNR dependence on contrastSwept icVEP response functions show SNR is contrast dependent and rises as contrast increases (Xu et al. 2017).

Diagnostic contextCutoff selection affects sensitivity and specificity; different cutoffs (eg, 0.85 vs 1.0) produced varying sensitivity/specificity in POAG studies.

References count for coding section

References cited in policy11 references listed in the policy's reference section.

Representative topicsReferences include studies on icVEP, NCS in inflammatory myopathies, sEMG in spinal cord injury, monofilament testing, and comparative ultrasound vs EMG/NCS.

Primary icVEP citationXu et al. 2017 is cited for icVEP diagnostic accuracy and reported SNR cutoffs.

Wearable seizure device validation and safety justification: Prior authorization requests for wearable seizure-detection devices (including sEMG-based systems or multi-sensor wearables) should include documentation demonstrating device clinical validation for the seizure type claimed (currently evidence supports use for generalized tonic-clonic seizures [GTCS] and focal to bilateral tonic-clonic seizures [FBTCS] only) and a clear safety rationale (for example, unsupervised individuals at risk of delayed intervention where an alarm can reasonably enable rapid response). Provide device performance metrics (sensitivity, false alarm rate, positive predictive value) derived from peer-reviewed studies or regulatory submissions and describe how alarms will be managed clinically.

Documented clinical validation for GTCS/FBTCS detection (sensitivity, FAR, PPV).
Clinical safety justification for use in unsupervised individuals and plan for alarm response.
Limitations: current evidence does not support wearable devices for seizure types other than GTCS/FBTCS.

Prior Authorization

Prior authorization evidentiary support

Prior authorization evidentiary support: When requesting coverage for investigational or limited‑evidence modalities (for example, wearable sEMG seizure detection, icVEP for glaucoma, or other non‑standard physiologic monitoring), include (at minimum): a concise clinical rationale, device manufacturer information and FDA status/clearance, peer‑reviewed performance data (sensitivity, specificity, FAR, PPV), description of testing protocol and placement, and how results will alter clinical management. For sEMG seizure devices, submit EMU/video‑EEG validation data if available and specifics on recording duration and expected alarm burden.

Clinical rationale and intended clinical impact.
Device identification and FDA clearance/510(k) status when applicable.
Published performance metrics and study context (EMU vs outpatient/community).
Detailed testing protocol, placement, and expected false alarm rate.

Billing Rule

Updated applicable codes and prior authorization implications

Updated applicable codes and prior authorization implications: Applicable procedure and HCPCS/CPT codes listed in this policy are for reference and benefit verification. Note that CPT/HCPCS codes 95999 and A9279 have been removed from the applicable code list; providers must confirm current applicable codes and whether prior authorization is required for a given service before submission. Removal of legacy or miscellaneous codes may result in claim denials if an alternative specific code is not used.

Removed codes: 95999, A9279 (01/01/2026 policy update).
Providers should verify member benefit plan and confirm current applicable CPT/HCPCS codes and prior authorization requirements.

Denial Risk

Denial risk for unproven tests and performance issues

Denial risk for unproven tests and performance‑related denials: Services identified in this policy as investigational or not medically necessary (for example, macro‑EMG, sMMG, many wearable accelerometer/EDR/gyroscope seizure monitors, non‑validated SEMG systems, automated point‑of‑care NCS screening devices that do not provide full waveform assessment, isolated quantitative sensory testing without validated methodology) may be denied due to insufficient evidence of efficacy or reproducibility. High false alarm rates, variable sensitivity across studies, or lack of validated clinical utility increase the likelihood of denial.

Unproven/not medically necessary examples: macro‑EMG, sMMG, SEMG seizure monitoring (when unvalidated), non‑invasive automated point‑of‑care NCS screening devices for diagnostic EDX use.
Performance-related risks: high FAR or low PPV may lead to determinations of not clinically useful.

Documentation Required

Supervision and equipment standards

Supervision, equipment, and performance standards: Testing must follow professional society standards. NCS and related studies should be performed using equipment that records complete waveforms and all relevant parameters (screening devices that only report distal motor latencies or limited metrics are not acceptable for diagnostic EDX evaluation). Needle EMG must be performed by a physician trained in EDX medicine; NCS may be performed by a trained technologist under direct or immediate availability supervision per AANEM guidance. One supervising physician should oversee and be responsible for the integrated EDX evaluation, and NCS and needle EMG should generally be performed and interpreted in real time on the same day.

Equipment must provide full waveform assessment; screening‑only instruments are not adequate for diagnostic testing.
Needle EMG: performed by a physician specially trained in EDX.
NCS: may be delegated to trained technologist under physician supervision; physician must be immediately available and review results.
One physician should supervise and perform components and provide integrated, real‑time interpretation.

Documentation Required

Recommended documentation and performance standards

Recommended documentation and required supervision: Document a focused clinical history, differential diagnosis, relevant physical examination findings, and the specific clinical question the electrodiagnostic testing is intended to answer. Record which nerves and muscles were tested, stimulation parameters, electrode placement, waveform tracings, interpretation, and an integrated report that includes both NCS and EMG findings. For delegated testing, document the training/credentials of the technologist and the supervising physician’s review and concurrence with the testing plan and final interpretation.

History and exam that justify testing and differential diagnosis.
Detailed test protocol: nerves/muscles tested, parameters, electrode placement, waveforms.
Integrated reporting of NCS and EMG together; document physician supervision and technologist credentials.

Documentation Required

Device data, instrument calibration, and clinical interpretation

Device data, calibration, and clinical interpretation: When device‑derived objective data (e.g., PKG, KinetiGraph, wearable biosensor outputs, or sEMG summaries) are used to guide care or referrals (such as for Device Assisted Therapy [DAT]), include device‑derived summaries, algorithm scores, dates and durations of monitoring, and the clinician’s interpretation of how the data informed management. Ensure instruments are validated for the intended use, follow manufacturer calibration schedules, and adhere to documented testing protocols to support reproducible results.

Provide objective device summaries, monitoring durations, algorithm/classifier scores and thresholds.
Document clinician interpretation and how results changed or informed management (e.g., DAT referral).
Include instrument calibration records and adherence to testing protocol/manufacturer recommendations.

Prior Authorization

Device FDA status and member benefit verification

Device FDA status and member benefit verification: Include the device name, manufacturer, and FDA classification or 510(k)/clearance details when available. Before applying this policy, verify member‑specific benefits and any applicable federal or state mandates—the member’s benefit plan governs coverage decisions and may differ from this policy. Providers should check benefit terms and prior authorization requirements prior to service.

Document FDA product code/clearance or statement if investigational.
Verify member‑specific benefit plan and any mandates before ordering/testing.
Policy guidance is informational; member benefit document controls coverage decisions.

Documentation Required

Use objective device data before DAT referral

Use of objective device data before advanced therapy referral: For referrals to advanced or device‑assisted therapies (e.g., DBS or other DAT), document objective monitoring data (such as multi‑day wearable recordings) and a clinician’s interpretation that supports the referral. Include duration of monitoring, algorithm outputs or classifier scores, and how the objective findings supplemented clinical assessment to justify the advanced therapy referral.

Supply multi‑day objective monitoring summaries and interpreter’s rationale for referral to DAT.
Show how device data altered management or confirmed the need for advanced therapy.

Late response testing (F-wave, H-reflex) are complementary components performed during the same evaluation and may be the sole abnormality in some cases.

Role with EMGA full electrodiagnostic evaluation typically involves both NCS and needle EMG to provide complementary diagnostic information.

QST (quantitative sensory testing) — definition

QST definitionQuantitative Sensory Testing (QST) is a noninvasive psychophysical method that measures sensory responses to stimuli such as touch, vibration, temperature, and pain to assess large- and small-fiber function.

Test modalitiesQST includes monofilaments, vibration threshold devices, thermal testing, pressure-specified sensory testing, and current perception threshold (sNCT/CPT) instruments.

LimitationsQST results are method- and subject-dependent; abnormal results are not specific to a particular neuropathy and reproducibility depends on protocol and cooperation.

Physiologic wearable monitors — definition

Physiologic wearable monitors definitionWearable devices using accelerometers, gyroscopes, and electrodermal sensors to record movement-, gait-, or seizure-related physiologic signals and to alert caregivers; used for ambulatory symptom monitoring over multiple days.

ApplicationsUsed for Parkinson disease motor symptom monitoring (multi-day kinematic data) and for seizure detection (EDA + accelerometry) to notify caregivers of potential events.

Data captureDevices typically store sensor data (EDA, accelerometry, temperature) for later review and may transmit real-time alerts to paired systems.

mfVEP definition

mfVEP definitionMultifocal visual evoked potential (mfVEP) assesses many visual field locations independently and concurrently to produce a topographical representation of visual pathway defects.

Use caseInvestigated as a method for diagnosing and monitoring glaucoma by evaluating cortical responses across multiple field locations.

Relation to VEPsmfVEP is a VEP variation that permits localized assessment versus conventional full-field VEPs.

NCS/EMG combined definition

NCS/EMG combined definitionNerve conduction studies (NCS) and needle electromyography (EMG) performed together provide complementary diagnostic information for peripheral nerve, neuromuscular junction, myopathy, and motor neuron disorders.

Clinical rationaleCombined testing helps localize lesions, distinguish neuropathic from myopathic processes, and guide treatment such as muscle localization for injections.

Professional standardA properly performed electrodiagnostic evaluation typically includes both NCS and needle EMG per AANEM guidance.

GTCS / FBTCS — seizure type definitions referenced

GTCS definitionGeneralized tonic-clonic seizure (GTCS): a seizure type for which clinically validated wearable detectors are conditionally recommended when safety concerns exist.

FBTCS definitionFocal to bilateral tonic-clonic seizure (FBTCS): focal seizures that evolve to bilateral tonic-clonic convulsions, also included in ILAE-IFCN recommendations for wearable detection when safety concerns exist.

ILAE-IFCN stanceILAE-IFCN gives a weak/conditional recommendation for using validated wearables for GTCS/FBTCS in safety-critical scenarios (eg, unsupervised sleeping individuals).

Quantitative Sensory Testing (QST) — definition entry

QST (alternate entry)Psychophysical testing measuring vibration, thermal, pressure and other sensory thresholds to assess small- and large-fiber function; methodology and reproducibility vary by instrument and protocol.

Clinical limitationsQST cannot localize dysfunction along the sensory axis and depends on patient cooperation; use should be limited to reproducible instruments/methodologies.

Research vs clinical useQST is used in both clinical and research settings, but evidence supporting predictive use for individual outcomes is weak/inconsistent.

QST — additional definition entry

QST detailsQST measures responses to touch, vibration, thermal, and pain stimuli; includes CPT/sNCT and pressure-specified sensory testing instruments.

Terminology cautionTerms like sensory nerve conduction threshold (sNCT) should not be confused with standard motor/sensory NCS measuring velocity, latency, and amplitude.

Interpretation noteAbnormal QST results are not specific to a particular neuropathy and require context from clinical evaluation.

sEMG — surface electromyography definition

sEMG definitionSurface electromyography (sEMG) is noninvasive recording of muscle electrical activity using skin electrodes, used for applications from seizure detection to respiratory and neuromuscular assessment.

SEMG-based seizure systemssEMG seizure monitoring systems (eg, arm/biceps patches) analyze surface EMG signals associated with generalized tonic-clonic seizures and provide caregiver alerts.

Advantages/limitationssEMG is noninvasive and feasible for monitoring, but studies report variable sensitivity and often high false alarm rates; device placement affects performance.

sMMG — surface mechanomyography definition

sMMG definitionSurface mechanomyography (sMMG) uses wearable sensors to measure mechanical muscle activity (often with IMU sensors) for assessing range of motion, posture, gait, and muscle function.

Relation to sEMGsMMG is considered the mechanical counterpart to sEMG, measuring physical muscle output during contractions.

Evidence statusFew published studies exist; insufficient evidence currently to conclude benefit on health outcomes.

icVEP — isolated‑check visual evoked potential definition

icVEP definitionIsolated‑check visual evoked potential (icVEP) is an electrophysiologic test measuring visual pathway responses (reported using signal-to-noise ratio, SNR) to detect glaucomatous dysfunction.

Measurement approachicVEP may use swept contrast steps to obtain response functions and calculate SNR at fundamental frequencies to evaluate visual function.

Clinical roleInvestigated as a complementary tool to standard automated perimetry and OCT for glaucoma detection, but generalizability is limited by small samples and protocol variability.

icVEP — additional icVEP definition and comparison to standard tests

icVEP comparison to standard testsSome studies found icVEP diagnostic performance comparable to standard automated perimetry (SAP) in early glaucoma detection, though not consistently superior.

Study limitationsCross-sectional studies and small samples limit conclusions; protocol/device differences affect results.

Recommended useicVEP may be used in conjunction with complementary functional and structural measures rather than as a broad replacement for standard tests.

Class II device — FDA regulatory classification definition

Class II device definitionClass II devices are FDA-regulated medical devices indicating moderate risk; multiple electrodiagnostic and sensory testing instruments (EMG, sEMG, QST, point-of-care NCS, VEP stimulators) are Class II with 510(k) clearances.

Examples by categoryProduct codes referenced include IKN (EMG), JXE (point-of-care NCS), LLN/GXB/LQW/GWI (QST instruments), and GWE/HLX (evoked response photic stimulators).

Regulatory implicationFDA Class II status provides informational context; device clearance does not equate to demonstrated clinical utility for all indications.

Key references listed (definitions-related references)

Key references countReference list includes studies on icVEP, NCS in inflammatory myopathies, sEMG in spinal cord injury, monofilament testing, and comparisons of ultrasound vs EMG/NCS.

Notable icVEP studiesXu et al. 2017 and Chen & Zhao 2017a are cited for icVEP diagnostic accuracy and comparisons to SAP.

sEMG evidence sourcesHalford et al. 2017 and systematic reviews/meta-analyses on sEMG and wearable seizure detection are referenced for performance and limitations.